Peer-reviewedCC BY-NC-ND 4.0iScience
IPO5 contributes to cetuximab resistance in colorectal cancer by modulating Ras signaling
Related
- Efficacy and safety of a cetuximab biosimilar compared with Erbitux in patients with RAS wild-type metastatic colorectal cancer
- Benzoylaconine suppresses colorectal cancer progression by modulating the CDK2/MMP2 signaling axis
- Acquired TRAIL Resistance Promotes Cancer Stemness and Malignant Behavior through CD44-SPHK1-STAT3 Signaling in Colorectal Cancer
- Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial
- GPR82-mediated activation of TGF-β/SMAD signaling contributes to CD8+ T cell dysfunction in HBV-ACLF
BibTeX
@article{yuan2026ipo5,
title = {{IPO5 contributes to cetuximab resistance in colorectal cancer by modulating Ras signaling}},
author = {Qinzi Yuan and Siqi Lu and Xiaoxi He and Lin Zheng and Lei Liu and Yujia Chen and Wenjuan Zhang and Xiaomin Li and Yanxia Lu and Xuenong Li},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117714},
url = {https://linkinghub.elsevier.com/retrieve/pii/S2589004226030956},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - IPO5 contributes to cetuximab resistance in colorectal cancer by modulating Ras signaling
AU - Qinzi Yuan
AU - Siqi Lu
AU - Xiaoxi He
AU - Lin Zheng
AU - Lei Liu
AU - Yujia Chen
AU - Wenjuan Zhang
AU - Xiaomin Li
AU - Yanxia Lu
AU - Xuenong Li
PY - 2026
DA - 2026/10/01
JO - iScience
DO - 10.1016/j.isci.2026.117714
UR - https://linkinghub.elsevier.com/retrieve/pii/S2589004226030956
SN - 2589-0042
ER -